A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Je Vrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

85 Scopus citations

Fingerprint

Dive into the research topics of 'A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients'. Together they form a unique fingerprint.

Medicine & Life Sciences